313 related articles for article (PubMed ID: 28246328)
1. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.
Dunn AR; Stout KA; Ozawa M; Lohr KM; Hoffman CA; Bernstein AI; Li Y; Wang M; Sgobio C; Sastry N; Cai H; Caudle WM; Miller GW
Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2253-E2262. PubMed ID: 28246328
[TBL] [Abstract][Full Text] [Related]
2. Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.
Dunn AR; Hoffman CA; Stout KA; Ozawa M; Dhamsania RK; Miller GW
Brain Res; 2019 Jan; 1702():85-95. PubMed ID: 29274878
[TBL] [Abstract][Full Text] [Related]
3. Synaptic vesicle glycoprotein 2C enhances vesicular storage of dopamine and counters dopaminergic toxicity.
Bucher ML; Dunn AR; Bradner JM; Egerton KS; Burkett JP; Johnson MA; Miller GW
Eur J Neurosci; 2024 May; 59(10):2483-2501. PubMed ID: 38532289
[TBL] [Abstract][Full Text] [Related]
4. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system.
Dardou D; Dassesse D; Cuvelier L; Deprez T; De Ryck M; Schiffmann SN
Brain Res; 2011 Jan; 1367():130-45. PubMed ID: 20869353
[TBL] [Abstract][Full Text] [Related]
5. A role for Sv2c in basal ganglia functions.
Dardou D; Monlezun S; Foerch P; Courade JP; Cuvelier L; De Ryck M; Schiffmann SN
Brain Res; 2013 Apr; 1507():61-73. PubMed ID: 23458503
[TBL] [Abstract][Full Text] [Related]
6. Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
Olsen AL; Clemens SG; Feany MB
Mov Disord; 2023 Feb; 38(2):244-255. PubMed ID: 36416213
[TBL] [Abstract][Full Text] [Related]
7. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family.
Janz R; Südhof TC
Neuroscience; 1999; 94(4):1279-90. PubMed ID: 10625067
[TBL] [Abstract][Full Text] [Related]
8. Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.
Peng C; Zhu G; Liu X; Li H
Neurosci Bull; 2018 Oct; 34(5):747-758. PubMed ID: 29713895
[TBL] [Abstract][Full Text] [Related]
9. Correlation of SV2C rs1423099 single nucleotide polymorphism with sporadic Parkinson's disease in Han population in Southern China.
Tan Z; Lin Y; Zhou M; Guo W; Qiu J; Ding L; Wu Z; Xu P; Chen X
Neurosci Lett; 2023 Sep; 813():137426. PubMed ID: 37544580
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
11. α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons.
Zaltieri M; Grigoletto J; Longhena F; Navarria L; Favero G; Castrezzati S; Colivicchi MA; Della Corte L; Rezzani R; Pizzi M; Benfenati F; Spillantini MG; Missale C; Spano P; Bellucci A
J Cell Sci; 2015 Jul; 128(13):2231-43. PubMed ID: 25967550
[TBL] [Abstract][Full Text] [Related]
12. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
Lotharius J; Brundin P
Hum Mol Genet; 2002 Oct; 11(20):2395-407. PubMed ID: 12351575
[TBL] [Abstract][Full Text] [Related]
13. Synaptic dysfunction in Parkinson's disease.
Picconi B; Piccoli G; Calabresi P
Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
[TBL] [Abstract][Full Text] [Related]
14. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.
Nemani VM; Lu W; Berge V; Nakamura K; Onoa B; Lee MK; Chaudhry FA; Nicoll RA; Edwards RH
Neuron; 2010 Jan; 65(1):66-79. PubMed ID: 20152114
[TBL] [Abstract][Full Text] [Related]
16. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
17. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.
Lam HA; Wu N; Cely I; Kelly RL; Hean S; Richter F; Magen I; Cepeda C; Ackerson LC; Walwyn W; Masliah E; Chesselet MF; Levine MS; Maidment NT
J Neurosci Res; 2011 Jul; 89(7):1091-102. PubMed ID: 21488084
[TBL] [Abstract][Full Text] [Related]
18. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
19. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment.
Iezzi M; Theander S; Janz R; Loze C; Wollheim CB
J Cell Sci; 2005 Dec; 118(Pt 23):5647-60. PubMed ID: 16306227
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein and dopamine at the crossroads of Parkinson's disease.
Venda LL; Cragg SJ; Buchman VL; Wade-Martins R
Trends Neurosci; 2010 Dec; 33(12):559-68. PubMed ID: 20961626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
